JP2012526854A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526854A5
JP2012526854A5 JP2012511068A JP2012511068A JP2012526854A5 JP 2012526854 A5 JP2012526854 A5 JP 2012526854A5 JP 2012511068 A JP2012511068 A JP 2012511068A JP 2012511068 A JP2012511068 A JP 2012511068A JP 2012526854 A5 JP2012526854 A5 JP 2012526854A5
Authority
JP
Japan
Prior art keywords
dispensing device
pharmaceutical composition
analgesic pharmaceutical
dexmedetomidine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012511068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526854A (ja
JP6172938B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/035136 external-priority patent/WO2010132882A2/en
Publication of JP2012526854A publication Critical patent/JP2012526854A/ja
Publication of JP2012526854A5 publication Critical patent/JP2012526854A5/ja
Application granted granted Critical
Publication of JP6172938B2 publication Critical patent/JP6172938B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012511068A 2009-05-15 2010-05-17 デクスメデトミジンの舌下組成物およびその使用方法 Expired - Fee Related JP6172938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15
US61/178,730 2009-05-15
PCT/US2010/035136 WO2010132882A2 (en) 2009-05-15 2010-05-17 Sublingual dexmedetomidine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015179975A Division JP2016029055A (ja) 2009-05-15 2015-09-11 デクスメデトミジンの舌下組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2012526854A JP2012526854A (ja) 2012-11-01
JP2012526854A5 true JP2012526854A5 (https=) 2013-07-04
JP6172938B2 JP6172938B2 (ja) 2017-08-02

Family

ID=43085620

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012511068A Expired - Fee Related JP6172938B2 (ja) 2009-05-15 2010-05-17 デクスメデトミジンの舌下組成物およびその使用方法
JP2015179975A Pending JP2016029055A (ja) 2009-05-15 2015-09-11 デクスメデトミジンの舌下組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015179975A Pending JP2016029055A (ja) 2009-05-15 2015-09-11 デクスメデトミジンの舌下組成物およびその使用方法

Country Status (21)

Country Link
US (1) US20110021588A1 (https=)
EP (2) EP2429521B1 (https=)
JP (2) JP6172938B2 (https=)
KR (1) KR101859486B1 (https=)
CN (2) CN102639131A (https=)
AU (1) AU2010248776B2 (https=)
BR (1) BRPI1010567A2 (https=)
CA (1) CA2762107A1 (https=)
CL (1) CL2011002858A1 (https=)
CO (1) CO6460767A2 (https=)
CR (1) CR20110596A (https=)
DO (1) DOP2011000354A (https=)
EC (1) ECSP11011459A (https=)
HN (1) HN2011003011A (https=)
IL (1) IL216159A (https=)
MX (1) MX2011011950A (https=)
NZ (1) NZ596976A (https=)
PE (1) PE20120713A1 (https=)
RU (1) RU2572692C2 (https=)
SG (1) SG175979A1 (https=)
WO (1) WO2010132882A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101948779B1 (ko) * 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
EP3554501B1 (en) * 2016-12-13 2021-06-09 Orion Corporation Dexmedetomidine or medetomidine for use in treating separation anxiety in companion animals
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
JP2025531884A (ja) * 2022-09-11 2025-09-25 バイオエクセル セラピューティクス，インコーポレイテッド 社会環境における激越の処置方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
EP1875917A3 (en) * 1990-12-05 2012-11-28 The General Hospital Corporation Use of NO for the treatment or prevention of reversible pulmonary vasoconstriction
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
MXPA01003310A (es) * 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2006105205A1 (en) * 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
ES2535233T3 (es) * 2006-01-25 2015-05-06 Insys Therapeutics, Inc. Pulverización de fentanilo sublingual
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
WO2008003093A2 (en) * 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Similar Documents

Publication Publication Date Title
JP2012526854A5 (https=)
IL216494A0 (en) Pharmaceutical dosage form oral administration of a bcl 2 family inhibitor
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
JP2012502037A5 (https=)
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
JP2013525444A5 (https=)
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PL2063861T3 (pl) Jednostka dawkowania do podawania podjęzykowego, podpoliczkowego lub doustnego nierozpuszczalnych w wodzie substancji aktywnych farmaceutycznie
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
MX2008011823A (es) Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
BRPI0807943A2 (pt) Composição farmacêutica ou nutracêutica e métodos para melhorar a administração de um ingrediente farmacêutico pela mucosa oral e para supressão de apetite
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
JP2011527299A5 (https=)
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2009022899A8 (es) Gel conteniendo pirfenidona
CL2007002574A1 (es) Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson.